AngioChem to Present at the 20th Annual Piper Jaffray Health Care Conference

The presentation by Dr. Jean-Paul Castaigne MD, MBA, President and Chief Executive Officer, will be on Tuesday, December 2nd at 4:10 pm.

Dr. Jean Paul Castaigne will provide a corporate overview and an update on the two on-going internal programs with anti-cancer agents and peptides as well as on the external research collaborations on siRNA and MAbs with a leader in the field.

About AngioChem

AngioChem is a Canadian clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases. The Company leverages a breakthrough platform technology capable of physiologically transporting any drug or drug candidate to the brain across the Blood-Brain Barrier. This approach creates patentable New Chemical Entities (NCEs). While validating its platform technology in clinical trials with ANG1005 for the treatment of brain cancer, the Company is also leveraging this technology to create a pipeline of other NCEs with small molecules, peptides, monoclonal antibodies and siRNA addressing brain diseases such as CNS cancer, neurodegenerative diseases and metabolic disorders. A detailed description of AngioChem's activities is available at www.angiochem.com.

www.angiochem.com